890839-26-6

Basic information

• Product Name: 1-benzyl-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one
• Synonyms: 1-benzyl-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one
• CAS NO: 890839-26-6
• Molecular Weight: 251.328
• Mol File: 890839-26-6.mol

Chemical Properties

• CAS DataBase Reference: 1-benzyl-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one(890839-26-6)
• EPA Substance Registry System: 1-benzyl-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one(890839-26-6)

Safety Data

• Hazardous Substances Data: 890839-26-6(Hazardous Substances Data)

Usage

Abbreviation

BDSA

Physical appearance

White to off-white crystalline solid

Usage

Pharmaceutical research and drug development

Chemical class

Benzazepinones

Receptor selectivity

Potent and selective antagonist for the dopamine D1 receptor

Targeted disorders

Neuropsychiatric disorders

Preclinical studies

Shown promising results for potential use in the treatment of cognitive and memory deficits

Neurotransmitter modulation

Investigated for its role in modulating the release of certain neurotransmitters

Analgesic potential

Investigated as a potential analgesic agent

Therapeutic potential

Versatile chemical with significant therapeutic potential

Research status

Subject of active research in the field of medicinal chemistry

Upstream product

• 446-52-6 2-Fluorobenzaldehyde 
• 1127-74-8 1,2,3,4-tetrahydro-5H-benzo[b] azepin-5-one 
• 100-39-0 benzyl bromide 

Downstream Products

• 890839-27-7 C₁₈H₂₀N₂O 

Relevant articles and documents

A Cascade of acid-promoted c-o bond cleavage and redox reactions: From oxa-bridged benzazepines to benzazepinones

A sequence of C-O bond cleavage and redox reactions in oxa-bridged azepines was realized under acid promoted conditions. This protocol provides an atom-economical and straightforward approach to access benzo[b]azepin-5(2H)-ones in high yields. The formal synthesis of tolvaptan was achieved by exploiting this new transformation.

HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.